Abstract
To correlate immunohistochemical expression patterns and prognosis in oesophageal adenocarcinoma. The expression of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor (EGFR) was studied in a series of 137 primarily resected oesophageal adenocarcinoma samples. The expression analysis on protein level was performed on routine paraffin wax-embedded material, with immunohistochemical staining of the samples, assembled on a tissue microarray. The results were correlated with clinicopathological features (pT, pN and G) and survival. 22 (16%) tumours showed an overexpression of the c-erbB-2 oncoprotein. Expression of EGFR was observed in 72 (55%) cases, accumulation of p53 in 68 (52%) cases and of cyclin D1 in 102 (77%) cases. Loss of p16INK4A expression was observed in 101 (76%) cases and low expression of p27KIP1 in 91 (71%) cases. Expression of these proteins did not correlate with tumour stage, grade, Lauren's or World Health Organization classification or lymph node status. On univariate survival analysis, more advanced tumour stage (p = 0.002), lymph node involvement (p = 0.003), high tumour grade (p = 0.017) and lack of EGFR expression (p = 0.034) were found to be associated with poorer survival. On multiple regression analysis, only tumour stage (p = 0.03) and lymph node involvement (p = 0.004) were shown to have an association with the survival of the patient. The immunohistochemical expression of c-erbB-2 oncoprotein, cylin D1, p16INK4A, p27KIP1, p53 and EGFR in most oesophageal adenocarcinomas suggests their implication in the pathogenesis of this entity. None of the molecular markers assessed, however, was of prognostic value. Identification of any marker superior to or even approaching the prognostic value of conventional histopathological markers (pT and pN) was therefore not possible.
MeSH Terms
Adenocarcinoma/metabolism,pathology,surgery
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor/metabolism
Cyclin D1/metabolism
Cyclin-Dependent Kinase Inhibitor p16/metabolism
Cyclin-Dependent Kinase Inhibitor p27/metabolism
Epidemiologic Methods
ErbB Receptors/metabolism
Esophageal Neoplasms/metabolism,pathology,surgery
Female
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Proteins/metabolism
Neoplasm Staging
Prognosis
Protein Array Analysis/methods
Receptor, ErbB-2/metabolism
Tumor Suppressor Protein p53/metabolism
Chemicals
Biomarkers, Tumor
Cyclin-Dependent Kinase Inhibitor p16
Neoplasm Proteins
Tumor Suppressor Protein p53
Cyclin D1
Cyclin-Dependent Kinase Inhibitor p27
ErbB Receptors
Receptor, ErbB-2
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Langer R
Institut für Pathologie, Technical University, München, Germany. Rupert.Langer@lrz.tum.de
Von Rahden B H A
Nahrig J
Von Weyhern C
Reiter R
Feith M
Stein H J
Siewert J R
Höfler H
Sarbia M
References (31)
31 references, click to expand
-
Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma.
J Gastrointest Surg. 2004 May-Jun;8(4):448-53
PMID: 15120370
-
Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system.
Mod Pathol. 2004 May;17(5):579-87
PMID: 15073595
-
p27 and Barrett's esophagus: a review*.
Dis Esophagus. 2004;17(2):113-7
PMID: 15230722
-
Molecular biology of upper gastrointestinal malignancies.
Semin Oncol. 2004 Aug;31(4):476-86
PMID: 15297940
-
Perspectives in tissue microarrays.
Comb Chem High Throughput Screen. 2004 Sep;7(6):575-85
PMID: 15379629
-
p53 function and dysfunction.
Cell. 1992 Aug 21;70(4):523-6
PMID: 1505019
-
Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas.
Int J Cancer. 1993 May 8;54(2):213-9
PMID: 8098013
-
p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
Gastroenterology. 1993 Dec;105(6):1637-42
PMID: 8253340
-
Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations.
J Clin Pathol. 1994 Jan;47(1):23-6
PMID: 7907608
-
Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
Cancer. 1994 Apr 1;73(7):1785-94
PMID: 7907940
-
p53 correlates with improved survival in patients with esophageal adenocarcinoma.
J Surg Oncol. 1995 Apr;58(4):269-73
PMID: 7723372
-
The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.
Ann Surg. 1995 Jun;221(6):677-83; discussion 683-4
PMID: 7794072
-
Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
J Thorac Cardiovasc Surg. 1996 Feb;111(2):323-31; discussion 331-3
PMID: 8583805
-
p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.
Cancer. 1997 Feb 1;79(3):425-32
PMID: 9028350
-
Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis.
Eur J Surg Oncol. 1997 Feb;23(1):30-5
PMID: 9066744
-
Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Mod Pathol. 1997 Feb;10(2):105-12
PMID: 9127315
-
Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
Cancer Res. 1998 Apr 15;58(8):1730-5
PMID: 9563491
-
Classification of adenocarcinoma of the oesophagogastric junction.
Br J Surg. 1998 Nov;85(11):1457-9
PMID: 9823902
-
Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach.
Hum Pathol. 1999 Sep;30(9):1087-92
PMID: 10492044
-
p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Cancer Lett. 2005 Jan 20;217(2):221-30
PMID: 15617840
-
The HER-2/neu oncogene in tumors of the gastrointestinal tract.
Cancer Invest. 2001;19(5):554-68
PMID: 11458821
-
P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Clin Cancer Res. 2000 Aug;6(8):3153-8
PMID: 10955797
-
New molecular concepts of Barrett's esophagus: clinical implications and biomarkers.
J Surg Res. 2005 May 15;125(2):189-212
PMID: 15854673
-
Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus.
Aliment Pharmacol Ther. 2001 Aug;15(8):1087-100
PMID: 11472311
-
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.
J Pathol. 2001 Sep;195(1):72-9
PMID: 11568893
-
Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions.
Am J Clin Pathol. 2002 Jul;118(1):60-6
PMID: 12109857
-
Cell cycle-regulated factors in esophageal cancer.
Dis Esophagus. 2002;15(2):149-54
PMID: 12220423
-
Molecular and biologic basis of upper gastrointestinal malignancy--esophageal carcinoma.
Surg Oncol Clin N Am. 2002 Apr;11(2):257-72, viii
PMID: 12424849
-
Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.
J Thorac Cardiovasc Surg. 2003 May;125(5):1121-31
PMID: 12771886
-
Demystified...tissue microarray technology.
Mol Pathol. 2003 Aug;56(4):198-204
PMID: 12890740
-
Molecular biology of esophageal cancer.
Onkologie. 2004 Apr;27(2):200-6
PMID: 15138356